Choice Cancer Care has sold a majority interest to Cancer Treatment Centers America
The shareholder of Choice Cancer Care has sold a majority interest to Cancer Treatment Centers America. Financial details have not been disclosed.
Choice Cancer Care (CCC) is a QOPI certified medical and radiation oncology practice with six locations across North Texas. It is among the busiest practices in the country for brachytherapy, a prostate seed implant therapy.
Cancer Treatment Centers of America (CTCA) operates cancer treatment hospitals in Atlanta, Chicago, Philadelphia, Phoenix, and Tulsa and outpatient facilities in Chicago, Phoenix, and Scottsdale. With over 160 MDs, the company is highly regarded for its patient-centered philosophy, genomic and state-of-the-art technologies, wide array of precision treatment options, and comprehensive expertise across most cancer types.
Oaklins' team in Dallas contacted several strategic and private equity parties with a history of acquiring specialty practices. Typical metrics to value the business did not provide a profitable exit strategy. The team succeeded in cultivating good interest with a financially strong acquiror to expand its presence into North Texas and negotiated a highly profitable exit for the shareholder, including substantial cash, strong retention incentives, and continued ownership to monetize expansion efforts into underserved markets.
Talk to the deal team
Managing PartnerDallas, United States
Oaklins Capital Alliance
Gilde Healthcare has invested in Tandarts Today
Gilde Healthcare has invested in Tandarts Today, a fast-growing dental chain in the Netherlands. The investment will allow Tandarts Today to accelerate its buy-and-build strategy and become a leading dental chain in the Netherlands. Financial details have not been disclosed.Learn more
Alcidion (ASX:ALC) has acquired ExtraMed
Alcidion (ASX:ALC) has acquired ExtraMed Ltd., a UK provider of patient flow management software that helps address key pain-points for hospital administrative staff.Learn more
Alcidion (ASX:ALC) has completed a capital raise
Alcidion (ASX:ALC) has raised funds to continue its growth strategy.Learn more